Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported its financial results for the year and quarter ending December 31, 2022. For the full year, revenue increased 15% to $12.9 million, driven by a rise in EksoHealth product sales. However, the fourth quarter saw a revenue decline to $3.6 million from $4.1 million in Q4 2021. Gross profit also fell to $1.7 million, reflecting a reduced gross margin of approximately 47%. The net loss for 2022 was $15.1 million, higher than the previous year's loss. As of year-end, the company had $20.5 million in cash, down from $40.4 million a year earlier.

Ekso Bionics (Nasdaq: EKSO) will announce its financial results for Q4 and the full year 2022 on March 28, 2023, after market close. A conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial outcomes and recent business developments. Investors can access the live webcast on the company's website or call in directly. A replay of the webcast will be available for one month afterward. As a pioneer in exoskeleton technology, Ekso Bionics focuses on improving mobility and strength in medical and industrial sectors.

Ekso Bionics (Nasdaq: EKSO) announced its participation in the American Physical Therapy Association’s Combined Sections Meeting, showcasing the new Ekso Indego Therapy integrated with Functional Electrical Stimulation (FES). This innovative therapy aims to enhance rehabilitation for individuals with spinal cord injuries or strokes, offering ten customizable channels for muscle stimulation. The company filed a Premarket Notification 510(k) with the FDA to include this FES technology, marking a significant advancement in patient care. CEO Scott Davis emphasized the commitment to improving patient outcomes through this integration, expected to improve limb function and muscle strength.

Ekso Bionics has acquired the Human Motion and Control (HMC) Business Unit from Parker Hannifin for $10 million, enhancing its portfolio with the Indego lower limb exoskeleton line. This acquisition expands Ekso’s product offerings into home and community markets, aiming to improve patient accessibility to advanced robotic solutions for mobility impairments. The partnership with Vanderbilt University is expected to enhance research and product development. Scott Davis has been appointed as CEO, replacing Steven Sherman, who transitions to Executive Chair.

Ekso Bionics Holdings reported a record of 33 EksoNR bookings in Q3 2022, with revenues of $3.3 million, reflecting a 9.2% year-over-year increase. The nine-month revenue reached $9.4 million, a 30.6% increase from last year. Despite this growth, gross profit decreased by 6.7%, leading to a gross margin of 51%. The net loss for Q3 was $4.3 million, up from $2.0 million in the previous year. The company’s cash position stood at $29.2 million as of September 30, 2022, down from $40.4 million at the end of 2021, highlighting concerns over increasing operational costs.

Ekso Bionics Holdings (Nasdaq: EKSO) announced it will release its financial and business results for Q3 2022 on November 3, 2022, after market close. A conference call will follow at 1:30 p.m. PT to discuss these results and recent business developments. Investors can access the call by dialing 877-407-3036 (domestic) or 201-378-4919 (international), using Conference ID: 13733265. The call will be available for one month on their website.

Ekso Bionics, a leader in exoskeleton technology, announced its President and COO, Scott Davis, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available for on-demand viewing starting at 4:00 AM PT / 7:00 AM ET on September 12, 2022, and can be accessed through the investor section of the Ekso Bionics website. Founded in 2005, Ekso Bionics develops innovative wearable robots to enhance human strength and mobility for both medical and industrial applications.

Ekso Bionics reported a strong financial performance for Q2 2022, with revenue of $3.5 million, a 57% increase year-over-year. The company secured a 510(k) FDA clearance for its EksoNR device for Multiple Sclerosis patients and booked 17 units in the quarter. Despite these positives, the net loss for common stockholders grew to $3.0 million, compared to $1.3 million in Q2 2021. The gross margin decreased to 47% due to rising costs. Cash reserves stood at $31.9 million as of June 30, 2022.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced plans to release its second quarter 2022 financial results on July 28, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. Interested investors can access a live webcast via the company’s website. Ekso Bionics, established in 2005, focuses on developing exoskeleton solutions for medical and industrial applications, enhancing human capabilities through innovative wearable technology.